专利检索 ap:("DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION" OR "IMMUNOFORGE CO.,LTD.") AND inv:"Ji Young Kim" 第 1 页

1.

发明公开
3-((8-((1H-PYRAZOL-4-YL)AMINO)IMIDAZO[1,2-A]PYRIDIN-3-YL)ETHINYL)-N-PHENYLBENZAMIDE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER 审中-公开

公开(公告)号：US20230295153A1

公开(公告)日：2023-09-21

申请号：US17801757

申请日：2021-02-26

申请人： DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION , IMMUNOFORGE CO.,LTD.

发明人： Doohyun Lee , Seungyeon Lee , Ye Ri Han , Chun Young Im , So Young Kim , Nam Hui Kim , Hwan Geun Choi , Eunhwa Ko , Heegyum Moon , Sun Joo Lee , Sang Bum Kim , Hyo-Ji Kim , Sion Lee , Sung-Min Ahn , Kiho Chang , Eunkyu Lee , Hyun Jin Kwon , Myeong-Sook Jeong , Ji Young Kim

IPC分类号： C07D471/04 , A61P35/00

CPC分类号： C07D471/04 , A61P35/00

摘要： The present invention relates to a 3-((8-((1H-pyrazol-4-yl)amino)imidazo[1,2-a]pyridin-3-yl)ethynyl)-N-phenylbenzamide derivative, a method for preparing the same, and a pharmaceutical composition comprising the same as an active ingredient for preventing or treating cancer. The derivative can significantly inhibit the proliferation of cancer cells by inhibiting kinases, particularly Bcr-Abl kinase or Bcr-Abl (T315I) kinase. Therefore, the derivative can be effectively used as a pharmaceutical composition for the prevention or treatment of cancer.